GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025
NEW YORK, Oct. 23, 2017 /PRNewswire/ -- KEY FINDINGS
The global botanical and plant derivative drug market was calculated to be worth $ 37865 million in 2016. The market is projected to grow with a CAGR of 3.53% over the forecast period of 2017-2025, generating $51881 million by the end of 2025.
Read the full report: https://www.reportlinker.com/p05155343
MARKET INSIGHTS
The global market for botanical and plant-derived drugs is chiefly driven by their growing applications in diseases and the technological advancements in their manufacturing processes. The market is segmented on the basis of products, therapeutic applications, and derivative drug type. The products from these market include Herbal/traditional topical analgesics, pediatric dietary supplements, tonics and herbal/traditional remedies for a cough, cold and allergy (hay fever), digestive remedies and dermatological remedies. The market finds its application in areas like dermatology, hormone diseases, CNS disorders, oncology, etc. The botanical and plant derivative drug types include steroids, terpenes, glycosides, phenols, etc.
REGIONAL INSIGHTS
The global botanical and plant-derivative drug market is geographically segmented into regions of North America, Europe, Asia-Pacific and rest of the world. The Asia-Pacific market is predicted to account for the highest share of the global market by the end of the forecast period. This growth can be attributed to the rising demand for plant derivative drugs from the APAC countries. These countries report a high number of cases for infectious as well as respiratory diseases. In order to treat these diseases, the plant-based derivatives drugs are increasingly being preferred.
COMPETITIVE INSIGHTS
Pfizer and Abbott are two of the leading pharmaceutical companies that deal in botanical, and plant-derived drug markets. Some of the other key players competing in the global market include Bayer Healthcare Llc, Bristol-Myers Squibb, Bionova, Cura Pharm, GlaxoSmithKline, Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, Medigene, Lupin Ltd, Novartis International Ag, Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd), Piramal Phytocare Ltd., and Tasly Pharmaceuticals Inc.
Read the full report: https://www.reportlinker.com/p05155343
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article